Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,109 | 3,438 | 5,087 | 4,889 | 4,773 |
| Marketable Securities | 7,025 | 8,177 | 8,100 | 7,418 | 7,183 |
| Receivables | 347 | 549 | 433 | 447 | 672 |
| Other current assets | 7,146 | 7,560 | 7,464 | 3,544 | 3,496 |
| TOTAL | $18,627 | $19,724 | $21,084 | $16,298 | $16,124 |
| Non-Current Assets | |||||
| Investments And Advances | 0 | 1,593 | 1,593 | 2,119 | 2,119 |
| Other Non-Current Assets | 0 | 267 | 267 | 267 | 257 |
| TOTAL | $N/A | $1,860 | $1,860 | $2,386 | $2,376 |
| Total Assets | $18,627 | $21,584 | $22,944 | $18,684 | $18,500 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,845 | 2,472 | 2,421 | 1,807 | 2,173 |
| TOTAL | $2,845 | $2,472 | $2,421 | $1,807 | $2,173 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,845 | $2,472 | $2,421 | $1,807 | $2,173 |
| Shareholders' Equity | |||||
| Common Shares | 3,408 | 2,786 | 2,690 | 1,029 | 742 |
| Retained earnings | -210,778 | -205,960 | -204,068 | -201,573 | -200,469 |
| Other shareholders' equity | -303 | -316 | -403 | -397 | -416 |
| TOTAL | $15,782 | $19,112 | $20,523 | $16,877 | $16,327 |
| Total Liabilities And Equity | $18,627 | $21,584 | $22,944 | $18,684 | $18,500 |